Table 2.
Disease outcomes relative to gene expression of ALK, LTK, PTN, and MK in clinical cancer specimen.
| Study name in Oncomine | Cancer subtype | Outcome measure | ALK | LTK | PTN | MDK | |
|---|---|---|---|---|---|---|---|
| Brain tumors | Phillips brain | Astrocytoma | Dead at 3 Years Dead at 5 Years |
0.045 – | – – |
0.047 5.47E-05 | – 0.007 |
| French brain | Anaplastic Oligodendroglioma |
Dead at 3 Years Dead at 5 Years |
– – |
– – |
0.033 0.034 |
– – |
|
| Freije brain | Anaplastic Oligodendroglioma |
Dead at 3 Years | – | – | 0.019 | – | |
| Freije brain | Glioblastoma | Dead at 1 Year | – | 2.89E-04 | – | – | |
| Pomeroy brain |
Medulloblastoma | Dead at 1 Year | – | – | 0.004 | – | |
| Breast cancer | Boersma breast | Ductal breast carcinoma epithelia | Dead at 5 Years | 0.029 | – | – | – |
| Desmedt breast |
Invasive ductal carcinoma |
Dead at 5 Years | 0.003 | – | – | – | |
| Pawitan breast | Breast carcinoma | Dead at 3 Years Dead at 5 Years |
1.30E-04 7.90E-04 | – – |
– – |
– – |
|
| Loi breast | Breast carcinoma | Metas. at 3 Years Metas. at 5 years | 0.016 7.37E-04 | 0.034 – | – – |
– – |
|
| Minn breast 2 | Breast carcinoma | Metas. at 1 Year Metas. at 3 Years Metas. at 5 Years |
0.036 0.011 7.49E-04 |
– – 0.041 |
– – – |
– – – |
|
| Colon cancer | Kurashina colon |
Colon Adenocarcinoma |
Dead at 1 Year Dead at 3 Years |
– – |
0.008 0.002 |
– 0.032 |
– 0.028 |
| TCGA 2 colorectal |
Colon Adenocarcinoma |
Dead at 1 Year | – | 0.033 | – | – | |
| Smith colorectal | Colorectal Adenocarcinoma | Dead at 5 Years | 0.009 | – | – | 0.025 | |
| Lung cancer | Bild lung | Lung Adenocarcinoma |
Dead at 1 Year Dead at 3 Years |
4.35E-05 0.013 |
– 0.037 |
– – |
– – |
| Melanoma | Xu melanoma | Melanoma | Metastasis Dead at 3 Years |
0.017 – |
– 0.036 |
– – |
0.23 – |
| Ovarian cancer | Bild ovarian | Ovarian carcinoma | Dead at 1 Year | 0.041 | – | – | – |
| Tothill ovarian |
Ovarian serous Adenocarcinoma |
Recur. at 3 Years Recur. at 5 Years |
0.003 0.018 |
– – |
– – |
– – |
|
| Prostate cancer |
Taylor prostate 3 |
Prostate carcinoma | Recur. at 1 Year Recur. at 3 Years Recur. at 5 Years |
0.021 – 0.037 |
0.003 – – |
– – – |
0.014 0.035 – |
| All studies | Separate Studies n = 18 |
Studies (out of 18) that showed at least one outcome correlation of < 0.05 |
12 | 8 | 5 | 5 | |
Measures of disease outcome include overall survival (alive or dead at 1, 3, or 5 years), disease free or disease recurrence and metastasis free or occurrence of metastasis. mRNA expression levels of ALK, LTK, PTN, and MK were obtained and compared for the available disease outcomes. The respective p-value for these comparisons of expression levels with different disease outcomes are indicated. Details to the respective studies are available under the study names indicated in the first column (Oncomine.org; Rhodes et al., 2004, 2007). A total of 18 suitable studies were found and each of the p-values shown indicates a significant positive association of higher expression of the respective gene with worse outcome.